<DOC>
	<DOCNO>NCT01669070</DOCNO>
	<brief_summary>The purpose study demonstrate dose proportionality FF ( 50 microgram ( mcg ) , 100 mcg 200 mcg ) , administer single repeat dose NDPI contain FF formulate lactose . In addition , aim study determine absolute bioavailability FF single strip product use high strength product administer single dose multiple inhalation use 250 mcg intravenous ( IV ) FF . This , part-randomized , open-label , 4 way crossover study ( 4 period ) healthy adult subject . During period , subject receive FF morning serial pharmacokinetic ( PK ) sampling ( 10 day inhale treatment 3 day IV treatment ) safety assessment perform . Each period separate washout period least 7 day follow-up telephone call occur 7 -14 day last dose study drug . The total duration study approximately 13-14 week subject .</brief_summary>
	<brief_title>A Four-way Crossover , Single Repeat Dose Study Determine Dose Proportionality Absolute Bioavailability Fluticasone Furoate Inhalation Powder Administered Novel Dry Powder Inhaler ( NDPI )</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Healthy male female subject 18 65 year age body mass index ( BMI ) within range 18.5 29.0 kilogram/meter square . Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) bilirubin &lt; =1.5x upper limit normal ( ULN ) . Female subject child bear potential eligible enter pregnant willing use protocolspecified method contraception prevent pregnancy study . Average QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond . Forced Expiratory Volume 1 Second ( FEV1 ) &gt; = 85 % predict screening . Current nonsmoker Able satisfactorily use NDPI . Subjects must systolic blood pressure 145 milimeter ( mm ) mercury ( Hg ) diastolic pressure 85 mmHg screen visit . History breathe problem adult life confirm normal lung function parameter ( â‰¥85 % predict ) . Donation 500 mL blood within 56 day period . Subjects suffer low respiratory tract infection within 4 week screen visit . Current chronic history liver disease , know hepatic biliary abnormality . The subject treat diagnosed depression within six month screen history significant psychiatric illness . The subject positive : drug/alcohol , Hepatitis , HIV screen . Abuse alcohol . Subject positive cotinine urine alcohol test . Participated &gt; 3 clinical trial previous 10 month ( male ) , &gt; 2 clinical trial previous 10 month ( female ) , subject participate study ( include follow ) within 60 day prior first dose day current study . Exposure four new chemical entity within 12 month prior first dose day . Taken systemic , oral depot corticosteroid less 12 week inhale , intranasal topical steroid le 4 week screen visit . Use prescription nonprescription drug . History severe milk protein allergy , sensitivity study medication , include immediate delay hypersensitivity intranasal , inhaled systemic corticosteroid therapy . Pregnant lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>Fluticasone Furoate</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>dose proportionality</keyword>
</DOC>